SCHEMBL3306486

SCHEMBL3306486

Fc1c(F)c(C(F)(F)F)c(F)c(F)c1-c1ccc2scnc2c1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALOX5AP P20292 1/20 0.39
FEN1 P39748 1/20 0.39
FASN P49327 1/20 0.39
DYRK1A Q13627 1/20 0.37
RIPK2 O43353 7/20 0.36
TGFBR1 P36897 5/20 0.36
KDR P35968 3/20 0.36
LCK P06239 2/20 0.36
ALDH1A1 P00352 1/20 0.36
HSD17B10 Q99714 1/20 0.36
RIPK3 Q9Y572 1/20 0.36
TRPV3 Q8NET8 1/20 0.35
EGFR P00533 1/20 0.35
FFAR1 O14842 1/20 0.34
HSD11B1 P28845 1/20 0.34
APP P05067 1/20 0.34
PIK3CD O00329 1/20 0.33
MAP3K11 Q16584 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3307025 0.80 FASN (0.41) ALOX5APFEN1FASNDYRK1ARIPK2
SCHEMBL3307688 0.75 RXRA (0.42) ALOX5APFEN1FASNDYRK1ARIPK2
SCHEMBL28048502 0.75 ALDH1A1 (0.54) ALOX5APFEN1FASNDYRK1ARIPK2
SCHEMBL3307500 0.75 MPL (0.48) ALOX5APFEN1FASNDYRK1ARIPK2
SCHEMBL1851823 0.75 KIF11 (0.49) ALOX5APFEN1
SCHEMBL3311489 0.74 DYRK1A (0.46) ALOX5APFEN1FASNDYRK1ARIPK2
SCHEMBL3308095 0.72 PIK3CA (0.53) ALOX5APFEN1FASNDYRK1ARIPK2
SCHEMBL1538312 0.71 NPC1 (0.47) DYRK1AALDH1A1HSD17B10HSD11B1
SCHEMBL30375905 0.71 NPC1 (0.47) DYRK1AALDH1A1HSD17B10HSD11B1
SCHEMBL10354542 0.70 RIPK2 (0.60) ALOX5APFEN1DYRK1ARIPK2TGFBR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8420052-B2 Imaging agents useful for identifying AD pathology SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2013-04-16 US disclosed
US-8420052-B2 Imaging agents useful for identifying AD pathology SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2013-04-16 US disclosed
US-8420052-B2 Imaging agents useful for identifying AD pathology SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2013-04-16 US disclosed
US-20100098634-A1 Imaging Agents Useful for Identifying AD Pathology SIEMENS MEDICAL SOLUTIONS USA, INC. 2010-04-22 US disclosed
US-20100098634-A1 Imaging Agents Useful for Identifying AD Pathology SIEMENS MEDICAL SOLUTIONS USA, INC. 2010-04-22 US disclosed
US-20100098634-A1 Imaging Agents Useful for Identifying AD Pathology SIEMENS MEDICAL SOLUTIONS USA, INC. 2010-04-22 US disclosed
WO-2010011964-A2 IMAGING AGENTS USEFUL FOR IDENTIFYING AD PATHOLOGY SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2010-01-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100098634-A1 Imaging Agents Useful for Identifying AD Pathology APP, APBA1, PYGB ALOX5AP 275/4885FEN1 1545/4885FASN 2834/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.